Black Rock Inc. Delcath Systems, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 115,172 shares of DCTH stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

115,172

Previous 91,074 26.46%

Holding current value

$1.03 Million

Previous $434,000 121.89%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.47 - $8.37 $107,718 - $201,700	24,098 Added 26.46%	115,172 $963,000
Q1 2024 May 10, 2024	SELL	$3.72 - $5.09 $3,191 - $4,367	-858 Reduced 0.93%	91,074 $434,000
Q4 2023 Feb 13, 2024	BUY	$2.25 - $4.17 $102,424 - $189,826	45,522 Added 98.09%	91,932 $382,000
Q3 2023 Nov 13, 2023	SELL	$3.12 - $5.85 $2,402 - $4,504	-770 Reduced 1.63%	46,410 $187,000
Q2 2023 Aug 11, 2023	BUY	$5.38 - $7.96 $164,348 - $243,162	30,548 Added 183.67%	47,180 $275,000

Q1 2023 May 12, 2023	BUY	$3.46 - $6.0 $10,490 - $18,192	3,032 Added 22.29%	16,632 $95,000
Q4 2022 Feb 13, 2023	BUY	$2.59 - $3.71 $756 - $1,083	292 Added 2.19%	13,600 $48,000
Q3 2022 Nov 14, 2022	SELL	$3.1 - $4.8 $1,131 - $1,752	-365 Reduced 2.67%	13,308 $43,000
Q2 2022 Aug 12, 2022	SELL	$3.62 - $6.55 $792 - $1,434	-219 Reduced 1.58%	13,673 $55,000
Q1 2022 May 12, 2022	SELL	$5.64 - $7.95 $3,705 - $5,223	-657 Reduced 4.52%	13,892 $88,000
Q4 2021 Feb 10, 2022	BUY	$7.2 - $11.72 $5,436 - $8,848	755 Added 5.47%	14,549 $113,000
Q3 2021 Nov 09, 2021	SELL	$8.44 - $12.65 $15,242 - $22,845	-1,806 Reduced 11.58%	13,794 $144,000
Q2 2021 Aug 11, 2021	BUY	$9.54 - $15.1 $148,824 - $235,560	15,600 New	15,600 $197,000

Others Institutions Holding DCTH

# of Institutions

130

Shares Held

13M

Call Options Held

133K

Put Options Held

159K

View Full List

About DELCATH SYSTEMS, INC.

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $76.8M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

More about DCTH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account